Abstract: Graves’ ophthalmopathy (GO), or more accurately thyroidassociated ophthalmopathy, is a typical reason for morbidity and pain in patients with Graves' disease. Around 20-25% of patients with Graves' hyperthyroidism have medically evident GO at the time of diagnosis. We conducted our systematic review study by searching electronic database such as PubMed,Cochrane Library for the term: Graves ophthalmopathy or Graves orbitopathy, pathogensis and similar, crossed with specific treatment regimens and Cochrane highly sensitive search strategy for RCTs and reviews. We scanned references of all included trials and reviews identified for additional studies. Study selection We included all RCTs comparing treatment modalities for GO with placebo, no-intervention, or other treatment modalities. Existing proof shows the effectiveness of iv corticosteroids in reducing CAS in patients with moderate to serious GO. Intravenous pulse corticosteroids have a statistically substantial however small benefit compared to oral corticosteroids and triggers substantially less negative occasions. This treatment is restricted by expense and threat for unusual extreme unfavorable occasions.
Keywords: Graves Ophthalmopathy, Pathogenesis.
Title: Pathogenesis and treatment approaches of Graves Ophthalmopathy: Systematic review
Author: Yasir wadi alanazi, Bassam wadi alanazi, Rawan wadi alenazi, Raed Khalid raja alanazi
International Journal of Healthcare Sciences
ISSN 2348-5728 (Online)
Research Publish Journals
